We provide single-visit testing for abnormalities leading to cancer. Every year, 300K women die due to undiagnosed cervical cancer. To solve this problem, we started with a product – the Smart Scope® – in the gynac health / gynac oncology space which targets 2B women around the world. With that, we are looking at an opportunity worth USD 5-15B. Since commercialising the product in 2019, we are successfully implementing the product deployments in Indian private as well as public healthcare market and are receiving fantastic, positive user feedback. We are also receiving invites from outside India for a product launch. We would like to scale within India and reach out to one region outside India in 2020.
